Investments
39Portfolio Exits
7
Want to inform investors similar to JDRF T1D Fund about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Latest JDRF T1D Fund News
May 10, 2023
DiogenX , a Marsille, France-based biotech company focused on regenerating insulin-producing beta cells for the treatment of diabetes, raised €27.5M in Series A funding. Backers included Roche Venture Fund, Eli Lilly and Company, Omnes, Boehringer Ingelheim Venture Fund, JDRF T1D Fund, and Adbio partners. As part of the financing, David Evans joined DiogenX’s board of directors. The company intends to use the funds to advance the lead drug candidate towards clinical development in patients with type 1 diabetes (T1D). Led by Benjamin Charles, CEO, DiogenX is a biotech company focused on regenerating insulin-producing beta cells for the treatment of diabetes. Its lead program is focused on modulating the Wnt/β-catenin signalling pathway to regenerate pancreatic insulin-producing beta cells to offer a disease-modifying therapy for type 1 diabetes. It is currently in preclinical development. The company, co-founded by Patrick Collombat, Jean-Pascal Tranié and Benjamin Charles, is based in Marseille, France, with research labs in Nice, France. FinSMEs 10/05/2023
JDRF T1D Fund Investments
39 Investments
JDRF T1D Fund has made 39 investments. Their latest investment was in DiogenX as part of their Series A on May 5, 2023.
JDRF T1D Fund Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
5/10/2023 | Series A | DiogenX | $30.12M | No | 5 | |
10/17/2022 | Series C | Inversago Pharma | $69.06M | No | 7 | |
5/16/2022 | Series C | Kriya Therapeutics | $270M | No | Bluebird Ventures, CAM Capital, Dexcel Pharma, Foresite Capital, JDRF T1D Fund, Lightswitch Capital, Narya Capital, Patient Square Capital, QVT, Transhuman Capital, and Undisclosed Investors | 4 |
3/29/2022 | Unattributed VC | |||||
9/15/2021 | Series B |
Date | 5/10/2023 | 10/17/2022 | 5/16/2022 | 3/29/2022 | 9/15/2021 |
|---|---|---|---|---|---|
Round | Series A | Series C | Series C | Unattributed VC | Series B |
Company | DiogenX | Inversago Pharma | Kriya Therapeutics | ||
Amount | $30.12M | $69.06M | $270M | ||
New? | No | No | No | ||
Co-Investors | Bluebird Ventures, CAM Capital, Dexcel Pharma, Foresite Capital, JDRF T1D Fund, Lightswitch Capital, Narya Capital, Patient Square Capital, QVT, Transhuman Capital, and Undisclosed Investors | ||||
Sources | 5 | 7 | 4 |
JDRF T1D Fund Portfolio Exits
7 Portfolio Exits
JDRF T1D Fund has 7 portfolio exits. Their latest portfolio exit was TetraGenetics on September 13, 2021.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
|---|---|---|---|---|---|
9/13/2021 | Acquired | 1 | |||
Date | 9/13/2021 | ||||
|---|---|---|---|---|---|
Exit | Acquired | ||||
Companies | |||||
Valuation | |||||
Acquirer | |||||
Sources | 1 |
JDRF T1D Fund Team
4 Team Members
JDRF T1D Fund has 4 team members, including current Managing Director, Katie Ellias.
Name | Work History | Title | Status |
|---|---|---|---|
Katie Ellias | Endeavour Vision, Sofinnova Partners, Medtronic, Partners Healthcare, and McKinsey & Company | Managing Director | Current |
Name | Katie Ellias | |||
|---|---|---|---|---|
Work History | Endeavour Vision, Sofinnova Partners, Medtronic, Partners Healthcare, and McKinsey & Company | |||
Title | Managing Director | |||
Status | Current |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.